Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
Takeda Pharmaceutical has sealed a partnership pact with PRA Health Sciences under which the US CRO will serve as a primary strategic partner for the Japanese drug major’s clinical development and post-approval needs, the two companies said on September 13.…
To read the full story
Related Article
- As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
BUSINESS
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
- Six Eisai Executives Took Home Over 100 Million Yen in FY2025
June 16, 2026
- Hisamitsu to Raise Prices on Salonpas, Other OTC Products
June 16, 2026
- Eisai to Invest £48 Million to Build Cold-Chain Capability in UK
June 16, 2026
- Susmed Bags 240 Million Yen Milestone for Tinnitus App
June 16, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…